|
ATE509033T1
(de)
|
2006-03-20 |
2011-05-15 |
Univ California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
KR101837053B1
(ko)
*
|
2008-10-01 |
2018-03-12 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP3904391B1
(en)
|
2010-03-10 |
2024-07-10 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
US9169329B2
(en)
|
2010-06-01 |
2015-10-27 |
Ludwig Institute For Cancer Research |
Antibodies directed to the receptor tyrosine kinase c-Met
|
|
JP2013533746A
(ja)
|
2010-07-06 |
2013-08-29 |
アベオ ファーマシューティカルズ， インコーポレイテッド |
抗ｒｏｎ抗体
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
WO2012076190A1
(en)
*
|
2010-12-10 |
2012-06-14 |
Merck Patent Gmbh |
Bispecific aptamers mediating tumour cell lysis
|
|
DE102011118022B4
(de)
*
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
*
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013078223A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Hospital & Research Center Oakland |
Anti-factor h binding protein antibodies and methods of use thereof
|
|
AR089114A1
(es)
|
2011-12-09 |
2014-07-30 |
Amgen Res Munich Gmbh |
PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
|
|
JP6284181B2
(ja)
*
|
2012-02-09 |
2018-02-28 |
国立研究開発法人理化学研究所 |
環状ｒｎａ及びタンパク質の製造方法
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
EP2708556B1
(en)
|
2012-09-12 |
2018-11-07 |
Samsung Electronics Co., Ltd |
Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
KR102391731B1
(ko)
*
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US20160015749A1
(en)
*
|
2013-03-05 |
2016-01-21 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
EP3587448B1
(en)
*
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN103275225A
(zh)
*
|
2013-05-10 |
2013-09-04 |
洪建� |
高亲合力抗cd31/cd146双特异单克隆抗体及其应用
|
|
US10196446B2
(en)
*
|
2013-10-14 |
2019-02-05 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type III domain binding molecules
|
|
KR102272932B1
(ko)
|
2013-10-25 |
2021-07-05 |
싸이오서스 테라퓨틱스 엘티디. |
이종 유전자로 무장된 종양살상 아데노바이러스
|
|
ES2959480T3
(es)
|
2014-02-07 |
2024-02-26 |
Univ Mcmaster |
Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
KR20170017916A
(ko)
*
|
2014-05-13 |
2017-02-15 |
추가이 세이야쿠 가부시키가이샤 |
면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
|
|
WO2015172341A1
(zh)
*
|
2014-05-14 |
2015-11-19 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
ES2743809T3
(es)
*
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
KR101615619B1
(ko)
*
|
2014-08-07 |
2016-04-26 |
주식회사 파멥신 |
c-Met 특이적 인간 항체 및 그 제조방법
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
JP2017536341A
(ja)
*
|
2014-10-09 |
2017-12-07 |
エンクマフ アーゲー |
卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
|
|
EP3204415B1
(en)
*
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
KR102309881B1
(ko)
|
2014-11-21 |
2021-10-06 |
삼성전자주식회사 |
c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
|
|
BR112017010793A2
(pt)
*
|
2014-11-24 |
2017-12-26 |
Regeneron Pharma |
animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US20170096485A1
(en)
*
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
MX390128B
(es)
|
2015-10-26 |
2025-03-20 |
Pf Medicament |
Composición para el tratamiento de cáncer con expresión del igf-1r.
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
CN106810610A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
|
CN106810611A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
|
TW201720458A
(zh)
*
|
2015-12-04 |
2017-06-16 |
宏觀基因股份有限公司 |
能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
US11155622B2
(en)
|
2015-12-17 |
2021-10-26 |
Psioxus Therapeutics Limited |
Virus encoding an anti-TCR-complex antibody or fragment
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
EP3478722A1
(en)
*
|
2016-06-30 |
2019-05-08 |
F. Hoffmann-La Roche AG |
Improved adoptive t-cell therapy
|
|
CN107573416A
(zh)
*
|
2016-06-30 |
2018-01-12 |
中国科学院深圳先进技术研究院 |
抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
|
|
TWI790206B
(zh)
*
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
KR102491752B1
(ko)
|
2016-08-29 |
2023-01-26 |
싸이오서스 테라퓨틱스 엘티디. |
이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CR20220578A
(es)
|
2016-09-14 |
2023-01-17 |
Teneobio Inc |
Anticuerpos de unión a cd3
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
EP3559035A1
(en)
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
US11319371B2
(en)
|
2017-06-05 |
2022-05-03 |
Numab Therapeutics AG |
Anti-CD3 antibodies
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
JP7009517B2
(ja)
|
2017-06-21 |
2022-01-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
BR112020002636A2
(pt)
|
2017-08-10 |
2020-07-28 |
Grifols Diagnostic Solutions Inc. |
composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano
|
|
EP3694997A4
(en)
|
2017-10-12 |
2021-06-30 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
|
DE102017125150B4
(de)
*
|
2017-10-26 |
2019-10-10 |
Epiontis Gmbh |
Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
WO2019144707A1
(zh)
*
|
2018-01-26 |
2019-08-01 |
重庆精准生物技术有限公司 |
一种改良的铰链区及其在构建car骨架中的应用
|
|
CN112469477A
(zh)
*
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
IT201800009282A1
(it)
*
|
2018-10-09 |
2020-04-09 |
Metis Prec Medicine Sb Srl |
Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
|
|
TWI821474B
(zh)
*
|
2018-12-07 |
2023-11-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｃｄ３抗體及其藥物用途
|
|
CR20210326A
(es)
|
2018-12-21 |
2021-09-10 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
CA3133654A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
CN114729059A
(zh)
|
2019-09-11 |
2022-07-08 |
宾夕法尼亚大学董事会 |
包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法
|
|
EP4058466A1
(en)
|
2019-11-13 |
2022-09-21 |
Amunix Pharmaceuticals, Inc. |
Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
|
|
CN115916818A
(zh)
*
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
CN114829408B
(zh)
*
|
2019-12-20 |
2024-01-26 |
山东博安生物技术股份有限公司 |
用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
|
|
US11976133B2
(en)
*
|
2020-01-31 |
2024-05-07 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
WO2021167952A2
(en)
*
|
2020-02-20 |
2021-08-26 |
The Feinstein Institutes For Medical Research |
Agonist antibodies against endoglin and uses thereof
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
US11834512B2
(en)
|
2020-05-04 |
2023-12-05 |
The Regents Of The University Of California |
Inhibiting anti-ENPP1 antibodies
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
AU2021276327A1
(en)
*
|
2020-05-19 |
2022-12-01 |
City Of Hope |
Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
|
|
PH12022553407A1
(en)
|
2020-06-25 |
2024-04-22 |
Amunix Pharmaceuticals Inc |
Her-2 targeted bispecific compositions and methods for making and using the same
|
|
CN115698072B
(zh)
|
2020-07-01 |
2023-07-04 |
山东博安生物技术股份有限公司 |
抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
CN112063608B
(zh)
*
|
2020-08-27 |
2022-06-17 |
浙江工业大学 |
一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
|
CA3238406A1
(en)
*
|
2021-11-19 |
2023-05-25 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody and use thereof
|
|
US20240165213A1
(en)
*
|
2022-11-21 |
2024-05-23 |
Avstera Therapeutics Corp. |
mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER
|
|
JP7855148B2
(ja)
|
2023-02-10 |
2026-05-07 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法
|
|
US20240400696A1
(en)
|
2023-04-17 |
2024-12-05 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting epidermal growth factor receptor and methods for making and using the same
|
|
CN116790744B
(zh)
*
|
2023-06-30 |
2024-04-26 |
浙江大学 |
一种缺血性心脏病晚期纤维化干预靶点及其应用
|
|
TW202534086A
(zh)
*
|
2024-02-28 |
2025-09-01 |
香港商Ｆｂｄ生物製劑有限公司 |
抗ｐｓｃａ抗體及其用途
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|